Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05909501 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessment of Geriatric Evaluations Impact on New AML Guidance

Study acronym: AGE-ING
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 1, 2026 → Dec 1, 2027
See other at-risk trials from Abramson Cancer Center at Penn Medicine

Record History

  1. Primary and study completion pushed from Dec 1, 2026 to Dec 1, 2027 Eligibility criteria expanded, about 6 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 6 words
  2. Primary and study completion dates: Jul 1, 2025 to Dec 1, 2026v6
  3. Re-verified, no change to tracked fieldsv5
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 1, 2023 to Oct 25, 2023 · Site details revisedv4 Show 2 more changesShow less
    • Start date changed from estimate of Nov 1, 2023 to Oct 25, 2023
    • Site details revised
  5. Start date: Sep 1, 2023 to Nov 1, 2023v3
  6. Start date: Jul 1, 2023 to Sep 1, 2023v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.
Trial Details
NCT Number NCT05909501
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Bristol-Myers Squibb
Conditions AML, Adult
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov